ArticleCurrent microbiology2025
Characterization of Fibrinolytic Enzyme from Bacillus altitudinis S-CSR 0020 and Its Clot-Degrading Capacity.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombosis, the major cause of heart disease, is on the rise owing to the current lifestyle habits of the population. Current treatments using thrombolytics, although successful, are plagued by side effects and costs. Fibrinolytic enzymes derived from microbial sources are ideal substitutes for chemical thrombolytics. Bacillus altitudinis S-CSR 0020, a soil bacterium, was shown to efficiently produce fibrinolytic enzyme. In this study, we further purified the enzyme using a combination of ammonium sulfate precipitation and ion-exchange chromatography to achieve a purification fold of 7.8 and a yield of 7%. SDS-PAGE and zymogram analysis revealed that the enzyme was 95 kDa in size and exhibited high stability across a broad pH range (6-11) and high temperature (30-60 ℃) even after 24 h incubation, along with an optimum pH and temperature of 9 and 40 °C, respectively. Further characterization revealed that the fibrinolytic activity was maximum at 4% fibrin concentration, and 3% ferric chloride and 5% β-mercaptoethanol enhanced enzyme activity. Functional analysis revealed that the purified enzyme efficiently removed preformed clots in the capillary and microfuge tubes and exhibited anticoagulant activity. No adverse effects were observed in the goat hepatic portal vein upon application of the fibrinolytic enzyme. This enzyme also displayed antibacterial activity against Staphylococcus aureus. The anticoagulant, clot-degrading potential, and non-toxic nature of the purified fibrinolytic enzyme highlight its potential application in the treatment of thrombosis.
Indexed as
Identifiers
40035896What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.